The CLOCK-BMAL1 complex in circadian regulation: structure, mechanisms, and therapeutic targeting

The heterodimeric transcription factor CLOCK-BMAL1 functions as the central activator of the mammalian circadian clock. By integrating basic helix-loop-helix (bHLH) and PAS-domain interaction surfaces, it binds E-box DNA elements and drives rhythmic transcriptional programs that underlie 24-hour physiological and behavioral cycles.

This review consolidates recent structural and biochemical insights into CLOCK-BMAL1, outlines the assays used to discover and validate modulators, and evaluates emerging pharmacology-especially effects on amplitude versus period, cell-specific responses, and potential for chronotherapeutic timing.

Recent structural work reveals that CLOCK-BMAL1 is organized through a modular interface architecture that enables multivalent enhancer occupancy and facilitates coactivator recruitment, particularly CBP/p300, supporting robust transcriptional activation. Repression is imposed by Cryptochromes and Period proteins through defined contacts with the CLOCK-BMAL1 PAS-domain core, thereby tuning interaction affinity and timing across the circadian cycle. These mechanistic insights are beginning to translate into chemical strategies, including direct disruption of the CLOCK-BMAL1 interaction, allosteric ligands targeting the BMAL1 PAS-B pocket, and modulation by endogenous cofactors such as heme that can reshape DNA engagement. Across these approaches, pharmacological effects appear to diverge by mechanism, with distinct impacts on amplitude and period and evidence for cellular context-dependence, while the field continues to refine assay modalities that reliably link target engagement to functional circadian outcomes.

Collectively, advances in structure and mechanism position CLOCK-BMAL1 as a druggable protein-protein interaction target and support a rational path toward next-generation circadian modulators. Key challenges remain, including achieving selectivity over related bHLH-PAS paralogs such as NPAS2, resolving cofactor-bound holocomplex states on chromatin, and converting acute modulation into durable physiological benefit. Addressing these gaps should accelerate translation toward therapeutics that can be precisely tuned and timed to align with circadian biology.